Publicação

Antiphospholipid syndrome

Ver documento

Detalhes bibliográficos
Resumo:The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100 000 persons per year and the prevalence around 40-50 cases per 100 000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndrome
Autores principais:Cervera,Ricard
Outros Autores:Espinosa,Gerard
Assunto:Antibodies Anticardiolipin Antibodies Antiphospholipid Antiphospholipid Syndrome Stroke
Ano:2018
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Fundação para a Ciência e Tecnologia
Idioma:inglês
Origem:SciELO Portugal
_version_ 1868441724575023104
author Cervera,Ricard
author2 Espinosa,Gerard
author2_role author
author_facet Cervera,Ricard
Espinosa,Gerard
author_role author
country_str PT
creators_json_txt [{\"Person.name\":\"Cervera,Ricard\"},{\"Person.name\":\"Espinosa,Gerard\"}]
datacite.creators.creator.creatorName.fl_str_mv Cervera,Ricard
Espinosa,Gerard
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
datacite.titles.title.fl_str_mv Antiphospholipid syndrome
dc.creator.none.fl_str_mv Cervera,Ricard
Espinosa,Gerard
dc.format.none.fl_str_mv text/html
dc.identifier.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2018000400013
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.source.none.fl_str_mv Medicina Interna v.25 n.4 2018
dc.subject.none.fl_str_mv Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
dc.title.fl_str_mv Antiphospholipid syndrome
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100 000 persons per year and the prevalence around 40-50 cases per 100 000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndrome
dirty 0
eu_rights_str_mv openAccess
format article
id scielopt_4160cd9109813d2c8b77fba81b3a2dfd
identifier.url.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2018000400013
instacron_str SciELO
institution Fundação para a Ciência e Tecnologia
instname_str Fundação para a Ciência e Tecnologia
language eng
network_acronym_str scielopt
network_name_str SciELO Portugal
oai_identifier_str oai:scielo:S0872-671X2018000400013
organization_str_mv urn:organizationAcronym:scielo
person_str_mv Cervera,Ricard
Espinosa,Gerard
publishDate 2018
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
reponame_str SciELO Portugal
repository_id_str urn:repositoryAcronym:scielopt
service_str_mv urn:repositoryAcronym:scielopt
spelling Antiphospholipid syndromeCervera,RicardEspinosa,GerardAntibodiesAnticardiolipinAntibodiesAntiphospholipidAntiphospholipid SyndromeStrokeopen accesshttp://purl.org/coar/access_right/c_abf2http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2018000400013URLhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2018000400013URLHasVersion2018-12-01The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100 000 persons per year and the prevalence around 40-50 cases per 100 000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndromeSociedade Portuguesa de Medicina InternaMedicina Interna v.25 n.4 2018text/htmlengjournal articlehttp://purl.org/coar/resource_type/c_6501literature
spellingShingle Antiphospholipid syndrome
Cervera,Ricard
Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
status SINGLETON
subject.fl_str_mv Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
title Antiphospholipid syndrome
title_full Antiphospholipid syndrome
title_fullStr Antiphospholipid syndrome
title_full_unstemmed Antiphospholipid syndrome
title_short Antiphospholipid syndrome
title_sort Antiphospholipid syndrome
topic Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
topic_facet Antibodies
Anticardiolipin
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Stroke
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2018000400013
visible 1